PDS Biotechnology’s (PDSB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report released on Friday,Benzinga reports. They currently have a $21.00 price objective on the stock.

Several other equities analysts have also recently commented on the company. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

PDS Biotechnology Trading Down 0.5 %

PDS Biotechnology stock opened at $2.00 on Friday. PDS Biotechnology has a 52 week low of $1.53 and a 52 week high of $6.68. The firm has a market capitalization of $73.64 million, a PE ratio of -1.72 and a beta of 1.93. The business’s 50-day simple moving average is $3.19 and its 200-day simple moving average is $3.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84.

Hedge Funds Weigh In On PDS Biotechnology

Large investors have recently added to or reduced their stakes in the company. Tempus Wealth Planning LLC acquired a new position in PDS Biotechnology in the 2nd quarter valued at approximately $55,000. Ground Swell Capital LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $146,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.